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The present study investigated differences in symptom perception between a clinical sample with
medically unexplained symptoms (MUS) and a matched healthy control group. Participants (N  58, 29
patients) were told that they would inhale different gas mixtures that might induce symptoms. Next, they
went through 2 subsequent rebreathing trials consisting of a baseline (60 s room air breathing), a
rebreathing phase (150 s, which gradually increased ventilation, PCO2 in the blood, and perceived
dyspnea), and a recovery phase (150 s, returning to room air breathing). Breathing behavior was
continuously monitored, and dyspnea was rated every 10 s. The within-subject correlations between
dyspnea on the one hand and end-tidal CO2 and minute ventilation on the other were used to index the
degree to which perceived dyspnea was related to specific relevant respiratory changes. The results
showed that perceived symptoms were less strongly related to relevant physiological parameters in MUS
patients than in healthy persons, specifically when afferent physiological input was relatively weak. This
suggests a stronger role for top-down psychological processes in the symptom perception of patients with
MUS.
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Medically unexplained symptoms (MUS), or bodily symptoms
in the absence of an organic disease or physiological dysfunction,
are a widespread problem in modern society. Twenty-five to 50%
of primary care patients present with MUS (Burton, 2003; Katon,
Ries, & Kleinman, 1984; Kroenke, 2003), making it the most
common category of complaints in general medical practice (Kir-
mayer & Taillefer, 1997). In secondary care, prevalence rates are
even higher (Nimnuan, Hotopf, & Wessely, 2001). The high
prevalence of MUS constitutes a major theoretical, clinical, and
socioeconomical challenge (Nimnuan, Hotopf, & Wessely, 2000).
Interestingly, reporters of MUS are commonly marked by high
negative affectivity (NA). Trait NA is a mood-related disposition
to experience negative emotions. A robust association of trait NA
with enhanced symptom reports has been widely accepted in the
literature (for an overview, see Van Diest et al., 2005).
Several theoretical accounts of the underlying mechanisms of
MUS have been advanced (Rief & Barsky, 2005). The present
study takes a symptom perception perspective. The central as-
sumption of all accounts using this perspective is that there is no
simple one-on-one correspondence between peripheral physiolog-
ical changes and the perception of physical symptoms (see Rief &
Broadbent, 2007, for a review). Symptoms are not the direct result
of the passive registration of bodily changes but are modulated by
“top-down” cognitive processes. A selection mechanism is hypoth-
esized to play a role in the processing of somatic information so
that only a small proportion of it reaches the level of conscious-
ness. It serves a survival value that only motivationally important
somatic information warns the conscious brain to take action in
order to restore homeostatic balance (Craig, 2002) and that low-
intensity and/or irrelevant somatic information is filtered out and
kept below the perception threshold. This allows an optimal bal-
ance between caring for the internal homeostasis and keeping
resources available to respond appropriately to changing external
demands in the environment. The selection process is guided by
information in memory: Schematic information, conceived of as the
record of a personal learning history with somatic experiences—
including related beliefs, expectations, and negative affective
connotations—may influence the perception and appraisal of the
bodily condition (Brown, 2004; Van den Bergh, Stegen & Van de
Woestijne, 1997, 1998). It is therefore important to distinguish
between (interoceptive) sensations and symptoms, terms that are
often used interchangeably in the literature. An interoceptive sen-
sation refers to a sensory process related to perceiving information
from within the body, whereas a symptom refers to the experience
of such information in a negative manner. While the term sensa-
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tion is typically used to describe a sensory component as such, the
term symptom implies an appraisal process, involving a cognitive
elaboration and a negative affective quality. Symptom perception
accounts assume that MUS patients have dysfunctional
perceptual–cognitive and appraisal processes regarding somatic
information. However, empirical research providing support for
model-based predictions is only slowly accumulating (McFarlane,
Ellis, Barton, Browne, & Van Hooff, 2008; Rief & Broadbent,
2007). The degree of correspondence within a person between a
symptom report and the activity in a specific and relevant physi-
ological system can be considered indicative of the relative con-
tribution of physiological (bottom-up) and perceptual–cognitive
and appraisal (top-down) processes to the symptom experience. In
the present study, we wanted to investigate to what extent patients
with MUS differ from healthy controls regarding the degree to
which their symptom reports are physiology based.
In a previous study (Bogaerts et al., 2008), we compared the
perception of respiratory sensations versus respiratory symptoms
in a nonclinical sample of high habitual-symptom reporters with
healthy controls using a rebreathing test (Read, 1967): Participants
rebreathed in a bag filled with a hyperoxic mixture to prevent
hypoxia. Breathing accumulating levels of PCO2 stimulates minute
ventilation (MV, a product of frequency per minute and tidal
volume) and induces increasing levels of dyspnea (Banzett &
Moosavi, 2001; Wan et al., 2006, 2008); switching back to breath-
ing room air causes these changes to return to baseline. Through-
out the experiment, respiratory parameters and subjective ratings
were continuously monitored, and participants rated their subjec-
tive experience every 10 s using a computerized scale. All partic-
ipants went through two subsequent breathing trials in which each
trial consisted of a baseline (60 s), a rebreathing phase (150 s), and
a recovery phase (150 s). In one trial, the subjective rating con-
cerned a respiratory sensation (i.e., intensity of breathing), while in
the other trial the subjective rating concerned a respiratory symp-
tom (i.e., dyspnea). The within-subject correlations between the
ratings and the respiratory referents (MV, PCO2) were used as
measures of the correspondence between the subjective and ob-
jective responses. We found no differences in the perception of
neutral respiratory sensations between high habitual-symptom re-
porters and controls. Interestingly, when the same participants had
to focus on a respiratory symptom (i.e., breathlessness or dyspnea)
instead of a respiratory sensation, the association between the
respiratory referent and the dyspnea ratings was significantly
lower in high habitual-symptom reporters compared with control
participants, but only when the induced physiological responses
had a low intensity (recovery phase) and not when they had a high
intensity (rebreathing phase; Bogaerts et al., 2008).
These findings suggest that symptom perception in high-MUS
participants may be more guided by top-down processes than by
actual interoceptive information from physiological responses, but
only in situations in which the latter have a relatively low intensity.
Apparently, the presence of contextual cues previously associated
with symptom episodes (i.e., reference to symptoms, instructions
about likelihood of symptoms) has automatically triggered sche-
matic memory representations in high habitual-symptom reporters
and biased the somatic experience (see also Van den Bergh et al.,
1998). However, when physiological stimuli are intense—such as
those induced during the rebreathing phase—little room remains
for biasing top-down effects: Intense somatic stimuli may capture
attention in a largely stimulus-driven, bottom-up fashion, entering
awareness and motivating adaptive behavior in order to maintain
the integrity of the body (Craig, 2003).
A limitation of the study of Bogaerts et al. (2008) was that partic-
ipants were drawn from a rather homogeneous population of young
nonclinical students. In addition, the classification of participants as
high-MUS persons was based solely on their scores on a symptom
checklist and on their self-reported claim that no objective cause for
their symptoms had been found after clinical evaluation. In the present
study, we wanted to replicate the critical findings on symptom per-
ception (Bogaerts et al., 2008) in a clinical outpatient group covering
a broader age range and consulting in a pulmonary unit with MUS, as
diagnosed after profound clinical evaluation and medical tests. We
focused on the perception of medically unexplained dyspnea since—
contrary to pain, cardiac, or gastrointestinal symptoms—this research
domain is largely underinvestigated (von Leupoldt & Dahme, 2005).
Since dyspnea has an air hunger component, which is strongly related
to changes in PCO2, and an effort component, which is more related
to ventilation, we measured the within-subject correspondence be-
tween the dyspnea rating and both these underlying physiological
responses (Lansing, Im, Thwing, Legedza, & Banzett, 2000). Other
relevant psychological variables (i.e., trait NA, state anxiety) were
also measured to control for possible influences on the study results.
In line with our previous findings, we predicted to find less
physiology-based symptom perception in MUS patients compared
with healthy control participants. More specifically, we expected
more dissociation between perceived dyspnea and the relevant
respiratory measures in the patient group, yet only during sensory
input of weak intensity (baseline and recovery phase) and not of
strong intensity (rebreathing phase).
Method
Participants
Patients (N  29, all women) were recruited from the pneumol-
ogy department of a university hospital. They were referred by
their medical doctor or a specialist from within the hospital for
multiple somatic complaints, among which dyspnea was identified
as most bothersome and as the main reason for seeking health care.
None of the patients had received prior treatment. No objective
cause for their complaints could be identified after a systematic
medical and psychiatric work up—including the Structured Clin-
ical Interview for DSM–IV Axis I Disorders (SCID-I/P; First,
Spitzer, Gibbon, & Williams, 2001; van Groenestijn, Vierstra,
Kupka, Akkerhuis, & Nolen, 1997) administered by a trained
psychiatrist, thorough physical examination by several medical
experts, and a wide variety of medical tests.1 Control participants
(N 29, all women) were recruited from the general population by
means of local advertisements (flyers, posters, and the Internet).
The latter participants received 10 euro in return for participation.
1 For example, spirometry, D-dimer, CT thorax, chest X-ray, histamine
provocation test, electrocardiogram, echocardiogram, cycle-ergometry, tilt
table test, electroencephalogram, evoked potentials, electromyogram, brain
scan (NMR), gastroscopy, gastrointestinal tract X-ray, manometry, esoph-
ageal pH-impedance monitoring, abdominal echogram, feces and urine
test, and blood test.
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All patients could be classified as high-MUS reporters on the
basis of their score (100) on the Checklist for Symptoms in Daily
Life (Wientjes & Grossman,1994). Only low-MUS reporters
(score  75) were retained from the control group. These cutoff
scores have shown favorable discriminative power in earlier stud-
ies (Bogaerts et al., 2008; Bogaerts, Janssens, De Peuter, Van
Diest, & Van den Bergh, in press). For all MUS patients, multiple
symptoms were present over the past year and were rated as
moderate to severe. Patient and control group were matched for
age (M  36; range 18–59), body mass index (M  22; range
18–27), and educational level.
Exclusion criteria for all participants were a history of pulmonary,
cardiovascular, gastrointestinal, or neuromuscular disease, or other
medical conditions that likely affect exercise capacity, such as acute
illnesses, fever, or headache. Also participants with a major psychi-
atric condition—other than somatization disorder or undifferentiated
somatoform disorder (Brown, 2004)—were excluded, as well as preg-
nant or lactating women. Participants were instructed to abstain from
coffee, tea, or alcoholic beverages after midnight before participating
and were asked not to smoke prior to the experiment. The experi-
mental protocol was evaluated by the hospital’s medical ethics com-
mittee and considered in accordance with the Declaration of Helsinki
of the World Medical Association (2000).
Self-Report Measures
Checklist for Symptoms in Daily Life. The Checklist for
Symptoms in Daily Life, based on Wientjes and Grossman (1994),
contained the original 35 items and an additional 4 items. Exam-
ples of symptoms that were included in the questionnaire are
dizziness, joint pain, dyspnea, irregular heartbeat, lower back pain,
headache, inflated stomach, chest pain, and so forth. Participants
responded to the question “To what extent did you experience the
following symptoms over the past year?” on a 5-point scale (never,
seldom, sometimes, often, very often). The original instrument
(Wientjes & Grossman, 1994) is highly reliable and has been
proven to successfully distinguish MUS patients from panic dis-
order patients, patients with other anxiety disorders, and healthy
subjects (Grossman & de Swart, 1984; Han, Schepers, Stegen, Van
den Bergh, & Van de Woestijne, 2000; Han, Stegen, Schepers,
Van den Bergh, & Van de Woestijne, 1998). The internal consis-
tency reliability of the checklist in the present sample was high
(Cronbach’s coefficient   .96).
Positive and Negative Affect Schedule. Negative affectivity
(NA), an important correlate of unfounded symptom reporting
(Watson & Pennebaker, 1989), was assessed by the Dutch trait
version (Engelen, De Peuter, Victoir, Van Diest, & Van den Bergh,
2006) of the Positive and Negative Affect Schedule (PANAS;
Watson, Clark, & Tellegen, 1988). The NA scale of the PANAS
includes 10 negative adjectives for which participants had to
indicate (on a 5-point rating scale) to which extent they felt that
way in general. The reliability and construct validity of the
PANAS have been documented elsewhere (Engelen et al., 2006;
Watson, Clark, & Tellegen, 1988).
Concurrently perceived dyspnea. During each breathing
trial, perceived dyspnea was rated every 10 s, prompted by an
auditory cue, on a 0–100 computerized scale by means of a mouse
click. The scale was a vertical bar positioned in the middle of the
screen. On its right, verbal descriptors were positioned at every
10th step describing different levels of the experienced dyspnea:
none (0), very slight (10), slight (20), moderate (30), fairly severe
(40), severe (50), very severe (60), very severe (70), very severe
(80), very, very severe (90), intolerable (100). The nature and
spacing of the numbers and descriptive categories were based on a
modified Borg Scale (Borg, 1982).
State anxiety. State anxiety was assessed using a 9-point
Likert-type horizontal scale ranging from 1 (not at all anxious) to
9 (extremely anxious). Participants responded to the question
“How anxious do (did) you feel at this moment (during the past
breathing trial)?”
Apparatuses and Physiological Recordings
Participants went through two trials of a standardized rebreath-
ing test (Read, 1967). This test causes a progressive increase of
PCO2 in the blood resulting from rebreathing from a bag, initially
filled with a 5 l gas mixture of 5% CO2 and 95% O2. Breathing in
this closed hyperoxic circuit elicits a state of hypercapnia (but not
hypoxia), which compels a higher respiratory flow and ventilation
and causes feelings of dyspnea. Participants wore nose clips and
breathed through a mouthpiece connected to a Y-valve via a wide
vinyl tube ending on a pneumotachograph measuring air flow. A
stopcock enabled the experimenter to switch the participants’
breathing between room air and the rebreathing bag. Manipula-
tions of the setup were kept out of sight of the participants to
ensure that participants could rely on only the experienced bodily
changes for their online ratings. A small tube, connected directly to
the mouthpiece, permitted a continuous sampling of respiratory
gases that was fed to an infrared CO2 monitor to determine the
fractional end-tidal concentration of CO2 (FetCO2). Airflow wave-
forms and CO2 data were sampled at a rate of 20 Hz and stored on
a personal computer. All waveforms were visually inspected off-
line to eliminate technical abnormalities.
Subsequently, respiratory signals were treated breath by breath
to determine the following parameters: inspiratory time (Ti) and
expiratory time (Te) in seconds, inspiratory volume (Vi) and
expiratory volume (Ve) in milliliters, and fractional concentration
of end-tidal CO2 (FetCO2) in percent. Only inspiratory volume
was used as a measure of tidal volume (Vt). We focused on
FetCO2 and MV (respiratory rate [RR]  Vt), with RR  60/
(Te  Ti) because they are the closest physiological referents of
the dyspnea feeling experienced during the rebreathing test (Wan
et al., 2006, 2008).
Procedure
The participants were invited to take part in an experiment
investigating the effect of different air mixtures on breathing
behavior and subjective well-being. Upon participants’ arrival, we
collected written informed consent, assessed state anxiety, and
asked participants to fill out a general health questionnaire, the
Checklist for Symptoms in Daily Life, and the PANAS.
Subsequently, the participants were led to sit in a comfortable
chair in front of a computer screen. All other equipment was
placed in an adjacent room. Participants were told that they would
be inhaling different types of air mixtures that might induce
symptoms that would disappear immediately after the trial. Prior to
the first breathing trial, an exercise trial (only room air) allowed
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participants to become familiar with the mouthpiece, the nose clip,
and the online rating system.
Next, participants went through two subsequent breathing trials
with presentation order counterbalanced across subjects. One trial
(rebreathing only, further called R-trial) consisted of a baseline
(60 s) and a rebreathing phase (150 s). Immediately after maximal
dyspnea or after the participant indicated she felt like wanting to
stop, the mouthpiece was taken out and the trial stopped. The other
trial (rebreathing plus recovery, further called RC-trial) consisted
of a baseline (60 s of room air), a rebreathing phase (150 s of
rebreathing bag), and a recovery phase (unknown to the partici-
pant, the valve was switched to room air, starting a phase of 150 s
of room air breathing in the system while ratings continued being
collected). We intended the presence/absence of a recovery phase
(R-trial vs. RC-trial) in order to investigate the peak–end effect,
known from pain research (Kahneman, Fredrickson, Schreiber, &
Redelmeier, 1993), for dyspnea. (The peak–end effect is not
discussed in the present article.) A 15-min intertrial interval en-
sured full recovery from the trial. After each trial, participants had
to indicate on a 9-point scale how anxious they felt during the
breathing trial.
Prior to the first breathing trial, we checked whether the partic-
ipants understood the meaning of the concept dyspnea, which was
defined as an uncomfortable feeling of not having enough air, an
urge to breathe, or a feeling of having more difficulty in breathing,
compared with at the start of the experiment. In addition, it was
explained that “the symptoms may come and go throughout the
experiment, and it would be possible not to feel any symptoms at
all.” During each breathing trial, respiratory parameters were con-
tinuously measured.
Data Analysis
Group differences in trait NA were analyzed using an analysis
of variance (ANOVA), with MUS as the between-subject variable.
Trait NA was also added as a covariate to the main analyses. State
anxiety was analyzed using a repeated-measures ANOVA, with
moment of measurement as the within-subject variable (start of
experiment, R-trial, RC-trial) and MUS as the between-subject
variable.
To obtain a more detailed picture of the course of the different
parameters during each phase, we divided the baseline into six
equal time segments of 10 s each. Similarly, both the rebreathing
phase and the recovery phase were divided into five equal time
segments of 30 s each. Separate repeated-measures ANOVAs were
performed on—respectively—mean FetCO2, mean MV, and mean
concurrent dyspnea rating as dependent variables, with MUS as a
between-subject variable and time segment as a within-subject
variable. For the ANOVAs concerning the baseline and the re-
breathing phase, trial (R-trial, RC-trial) was added as an additional
within-subject variable. In order to control for possible between-
group differences during baseline, the mean value of the last time
segment of the baseline was added as a covariate to the analyses
for the rebreathing phase.2 Similarly, the mean value of the last
time segment of the rebreathing phase (of the RC-trial) was added
as a covariate to the analyses for the recovery phase.
Within-subject correlations were calculated between the dys-
pnea ratings and the physiological referents as a measure of
physiology-based symptom perception (i.e., the higher the corre-
lation, the more physiology-based the symptom perception), sep-
arately for the rebreathing phase and recovery phase of each trial.
In particular, two relationships were inspected: dyspnea–FetCO2
and dyspnea–MV. Since there were no missing data and dyspnea
ratings were made every 10 s over a 150-s trial, N  15, for every
within-subject correlation. A Fisher Z transformation was carried
out on all correlations before further analysis. Reported correla-
tions were back-transformed from the Fisher Z scores. To control
for range restriction, we also tested possible differences in the
variability (SD) of the measures.
Presentation order of the trials (order) was added as a between-
subject variable to all analyses. Greenhouse–Geisser corrections were
applied when appropriate, and ε values are reported. Follow-up com-
parisons between groups were made with either a priori tests or with
Tukey HSD a posteriori tests. The  was set at .05.
Results
Descriptives
MUS patients (M  25.45, SD  8.27) had significantly higher
scores on trait NA than did control participants (M  14.34, SD 
2.45); main effect of MUS, F(1, 56)  48.09, p  .01, p2  .46.
State anxiety differed in function of the moment of measurement;
main effect of moment of measurement, F(2, 108) 6.09, p .01,
ε  .92, p2  .10. A significant interaction between MUS and
moment of measurement, F(2, 108)  4.72, p  .05, ε  .92,
p
2  .08, further specified that control participants felt more anx-
ious after the rebreathing trials than at the start of the experiment
( p  .01), whereas their anxiety levels did not differ between both
trials (ns). Regarding the MUS patients, anxiety levels did not
change across moments of measurement (ns). In addition, no
significant group differences in state anxiety were found at any
moment of measurement (ns).
Detailed Picture of Each Phase
Baseline. A repeated-measures ANOVA was performed on,
respectively, mean FetCO2, mean MV, and mean dyspnea rating as
dependent variables, with MUS and order as between-subject
variables, and trial (R-trial, RC-trial) and time segment (six levels)
of the baseline as within-subject variables.
MUS patients reported significantly higher mean levels of dys-
pnea than did control participants during the baseline; main effect
of MUS, F(1, 54) 7.07, p .05, p2 .12. A main effect of time
segment, F(5, 270)  20.65, p  .01, ε  .32, p2  .28, was
further specified by a significant interaction with MUS, F(5,
270)  5.03, p  .01, ε  .32, p2  .09, showing that the
MUS-related difference in mean dyspnea ratings became stronger
further along the baseline, with significant effects at all moments
of measurement except for the first three time segments (the first
30 s of the baseline; see Figure 1, Panel A).
No MUS-related differences during the baseline were found for
mean MV nor for mean FetCO2 (see Figure 1, Panel A).
2 Because the mean values of dyspnea, MV, and FetCO2 for the last time
segment of the baseline did not differ between the R- and RC-trial, the
average of both trials for each parameter was used as covariate.
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Rebreathing phase. A repeated-measures ANOVA was per-
formed on, respectively, mean FetCO2, mean MV, and mean
dyspnea rating as dependent variables, with MUS and order as
between-subject variables, and trial (R-trial, RC-trial) and time
segment (five levels) as within-subject variables. The mean value
of the last time segment of the baseline was used as covariate.
No main effect of MUS appeared for mean dyspnea, but dys-
pnea increased overall; Time segment: F(4, 212) 65.97, p .01,
ε  .33, p2  .55. Also a significant three-way interaction be-
tween MUS, order, and trial emerged, F(1, 53)  4.55, p  .05,
p
2  .08. Within order R-RC, control participants reported a sig-
nificantly higher mean dyspnea rating in the R-trial compared with
the RC-trial ( p .05), whereas for MUS patients the opposite was
true ( p  .07). In the RC-trial in the second position, MUS
patients rated dyspnea significantly higher than did control partic-
ipants ( p  .01) and higher than the RC in the first position ( p 
.01). Within order RC-R, no significant differences were observed.
No other significant differences were found for the control partic-
ipants (see Figure 2). The standard deviation of the dyspnea ratings
was not influenced by the MUS variable.
No MUS-related differences were found for the physiological pa-
rameters (mean and standard deviation) during the rebreathing phase
(see Figure 1, Panel B). Only main effects of the time segment were
found, showing the expected increases in the physiological mea-
sures; MV: F(4, 212)  21.26, p  .01, ε  .41, p2  .29;
FetCO2: F(4, 212)  15.46, p  .01, ε  .33, p2  .23.
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Figure 1. Mean perceived dyspnea, mean minute ventilation (MV), and mean fractional end-tidal concentration
of CO2 (FetCO2) for patients with medically unexplained symptoms (MUS) and healthy control participants in
baseline (Panel A), rebreathing phase (Panel B), and recovery phase (Panel C). Data for baseline (Panel A) and
rebreathing phase (Panel B) are collapsed across rebreathing (R) and rebreathing plus recovery (RC) trials,
whereas data for the recovery phase (Panel C) include only the RC trial. p values refer to the main effect of MUS
on the dependent variable. Vertical bars denote 0.95 confidence intervals.
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Recovery phase. A repeated-measures ANOVA was per-
formed on, respectively, mean FetCO2, mean MV, and mean
dyspnea rating as dependent variables, with MUS and order as
between-subject variables, time segment (five levels) of the recov-
ery phase as within-subject variable, and the mean value of the last
time segment of the rebreathing phase as a covariate.
MUS patients reported more dyspnea than did controls, F(1,
53)  20.63, p  .01, p2  .28, and this difference became
stronger along the recovery phase; MUS  Time Segment: F(4,
212)  9.31, p  .01, ε  .53, p2  .15. Mean difference
(patients–controls) and p-value for time segment 1, 2, 3, 4, and 5
were, respectively, 3.62, p  .22; 11.98, p  .05; 21.05, p  .01;
22.30, p  .01; 24.68, p  .01. Panel C of Figure 1 shows a
significant decrease in dyspnea in the control participants at each
time segment, whereas MUS patients showed no further decrease
between the last two time segments.
Although no MUS-related differences were observed in mean
MV, MUS patients did have an overall lower mean FetCO2; main
effect of MUS: F(1, 53) 5.09, p .05, p2 .09 during recovery
compared with the control group. Nevertheless, FetCO2 during
recovery remained within normal levels (around 5%) for both
groups, whereas symptoms typically only occur at levels below
3.9% (Rafferty, Saisch, & Gardner, 1992; see Figure 1, Panel C).
The standard deviations of the different parameters during the
recovery phase were equal in both groups.
Within-Subject Correlation as Measure of
Physiology-Based Symptom Perception
Rebreathing phase. An ANOVA was performed on the
Fisher Z-transformed within-subject correlations between dyspnea
and MV, and between dyspnea and FetCO2 as dependent variables.
MUS and order were between-subject variables and Trial (R-trial,
RC-trial) a within-subject variable.
No significant main effects or interaction effects occurred (see
Table 1; see Note to Table 1 for F and p values related to the main
and interaction effects). Covarying for trait NA did not change the
results.
Recovery phase. An ANOVA was performed on the Fisher
Z-transformed within-subject correlations between dyspnea and
MV, and between dyspnea and FetCO2 as dependent variables, and
MUS and order as between-subject variables.
Dyspnea ratings of MUS patients were overall significantly less
related to physiological responses than were those of healthy
control participants; for dyspnea–MV: MUS: F(1, 54)  12.35,
p  .01, p2  .19; for dyspnea-FetCO2: F(1, 54)  6.33, p  .05,
p
2  .10, see Table 1. Order played a role in the correlation
between dyspnea and MV as the physiological referent, F(1, 54)
5.35, p  .05, p2  .09, showing that for all participants the
within-subject correlation was lower when an explicit recovery
phase had been part of the first breathing trial (order RC-R). Such
an order effect was lacking for the correlation with FetCO2, F(1,
54)  .12, p  .73, p2  .00. No other MUS  Order interactions
emerged; dyspnea-MV: F(1, 54)  1.30, p  .26, p2  .02;
dyspnea–FetCO2: F(1, 54)  .21, p  .65, p2  .00. Adding trait
NA as covariate did not change the MUS-related effects.
Discussion
The present study corroborates the finding, obtained in nonclini-
cal high habitual symptom reporters (Bogaerts et al., 2008), that
symptom reports of clinical MUS patients are less strongly related
to specific and relevant physiological responses than are those of
healthy controls. In addition, the results confirm that this greater
uncoupling in MUS patients between perceived dyspnea and spe-
cific physiological referents is apparent only with relatively weak
physiological activity (during recovery) and does not emerge when
afferent physiological activity is rather intense (during rebreath-
ing). The MUS effect in the recovery phase is further supported by
the between-subject findings showing that (a) both MUS patients
and healthy controls have end-tidal CO2 levels well above the
threshold for symptoms caused by hypocapnia, and (b) MUS
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Figure 2. Mean perceived dyspnea during the rebreathing phase for patients with medically unexplained
symptoms (MUS) and healthy control participants as a function of trial type and trial order (R  rebreathing;
RC  rebreathing  recovery). Error bars denote standard errors.
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patients have lower end-tidal CO2 levels than do control partici-
pants, precluding that their elevated symptoms would be caused by
hypercapnia. So, also at a group level, we can conclude that the
elevated dyspnea ratings in MUS patients during recovery cannot
be explained by differences in end-tidal CO2 levels. Although no
within-subject correlations could be calculated for the baseline
(not enough data points and a lacking variability of dyspnea ratings
in the control group), group-level data showed that the elevated
dyspnea ratings in MUS patients in the baseline cannot be ex-
plained by differences in the physiological parameters. This is in
line with the idea that the MUS-effect on physiology-based symp-
tom perception is specifically present at times of physiological
responses of low (but not high) intensity.
Our conjoint findings lend important support to the theoretical
model of Brown (2004), assuming that distorted symptom percep-
tion may occur when contextual cues automatically activate emo-
tional memory representations of previous symptom episodes.
In the current study, the instructions about the likelihood of symp-
toms during the trials may have activated these memory schemata
in MUS patients more than in control participants. The results
further suggest that, at times of intense physiological arousal
(rebreathing), data-driven processing of the afferent input predom-
inates, wiping out MUS-related differences in physiology-based
symptom perception. However, when sensory input becomes less
intense and more vague (baseline and recovery phase), more room
is left for biasing influences of schema-guided information pro-
cessing in MUS patients.
An important question is why “learned” symptom schemata
would be more easily activated in MUS patients compared to
healthy persons. Although symptom-related contextual cues at
times of weak peripheral afferent input can be assumed to be
common in daily life, such situations do typically not give rise to
inappropriate activation of memory representations of symptom
episodes in healthy people. One explanation may be that the
association between contextual cues and symptoms is stronger in
MUS patients (due to more frequent occurrences in the past);
another speculation is that MUS patients are less able to inhibit
inappropriate activations of symptom schemata. Further research is
needed to clarify this mechanism.
Within order R-RC of the present study, control group participants
reported a higher mean dyspnea rating in the rebreathing phase of the
R-trial compared with the RC-trial, whereas for the MUS patients the
opposite was true. These findings suggest habituation (decreased
response strength with repeated exposure to stimuli) of dyspnea
ratings in control participants, whereas MUS patients tend to
sensitize (increased reactivity to stimuli) in their subjective ratings
from the first to the second trial. In a previous study of our group
that used the rebreathing test, air hunger sensitivity (slope of the
response during rebreathing) tended to sensitize in high trait-
anxious persons, yet habituated in low trait-anxious persons (Wan
et al., 2006). Also, repetitive sigmoid stimulation has been shown
to induce rectal hyperalgesia in patients with irritable bowel syn-
drome but not in healthy controls (Munakata et al., 1997). Sensi-
tization has been suggested as one of the underlying mechanisms
for MUS (see symptom perception model of Rief & Barsky, 2005;
Ursin, 1997), possibly by reinforcing pathological affective feed-
forward loops in the brain and not being adequately counterregu-
lated by central inhibitory mechanisms. The findings of the present
study fit in with this assumption. Interestingly, however, including
an explicit recovery phase preceding a subsequent rebreathing trial
(order RC-R) seems to eliminate the repetition effect. Possibly, the
experience of decreasing symptoms within the context of the
rebreathing procedure induces extinction learning in-between two
respiratory challenges. This finding may have clinical implica-
tions: Having patients focus on the waxing and waning of symp-
toms within contexts that are associated with symptom episodes
may work as a protective factor in the process of chronification. In
addition, methods causing symptoms to diminish in such contexts
may provide corrective experiences with therapeutic implications.
This is an interesting area of future research.
State anxiety has also been found to influence symptom reports
independent of physiological arousal (Barsky, Orav, Delamater,
Table 1
Mean, Standard Deviation, and Range of the Original Within-Subject Correlations Dyspnea–MV Respectively Dyspnea–FetCO2 for
Control Participants and MUS Patients in Each Condition
Group
Dyspnea–MV Dyspnea–FetCO2
Rebreathing phase
Recovery phase
RC-trial
Rebreathing phase
Recovery phase
RC-trialR-trial RC-trial R-trial RC-trial
Controls
M 0.84 0.80 0.78 0.86 0.85 0.31
SD 0.15 0.16 0.17 0.11 0.14 0.47
Range .27, .98 .29, .96 .23, .96 .61, .99 .35, .97 .68, .96
Patients
M 0.72 0.75 0.45 0.82 0.81 0.00
SD 0.36 0.26 0.33 0.30 0.28 0.49
Range .40, .98 .08, .97 .90, .82 .61, .98 .08, .97 .75, .84
Note. MV  minute ventilation; FetCO2  fractional end-tidal concentration of CO2; MUS  medically unexplained symptoms; R-trial  rebreathing-
only trial; RC-trial  rebreathing-plus-recovery trial. F and p values for the rebreathing phase are as follows: Dyspnea–MV: MUS, F(1, 54)  1.15, p 
.29; Order, F(1, 54)  2.16, p  .15; Trial, F(1, 54)  .46, p  .50; MUS  Order, F(1, 54)  .13, p  .72; Trial  MUS, F(1, 54)  1.32, p  .26;
Trial  Order, F(1, 54)  .11, p  .74; Trial  MUS  Order, F(1, 54)  .01, p  .91. Dyspnea–FetCO2: MUS, F(1, 54)  .00, p  .98; Order, F (1,
54)  .20, p  .65; Trial, F(1, 54)  .01, p  .94; MUS  Order, F(1, 54)  .20, p  .65; Trial  MUS, F(1, 54)  .08, p  .78; Trial  Order, F(1,
54)  1.98, p  .16; Trial  MUS  Order, F(1, 54)  .04, p  .85.
232 BOGAERTS ET AL.
Clancy, & Hartley, 1998; De Peuter et al., 2007). As we did not
observe differences between MUS patients and control group
participants in anxiety levels—as measured at the start of the
experiment and after each breathing trial—higher rates for dys-
pnea in MUS patients during baseline and recovery phase are
likely not due to the patient group being more anxious than were
the control group participants.
What is interesting is that—although we did find a significant
main effect of MUS on trait NA—adding trait NA to the main
analyses as a covariate did not alter the results, meaning that MUS
has an effect on its own and cannot be reduced to the role of trait
NA. This finding should be taken into account in theorizing about
possible explanations for the NA–symptom relationship.
The fact that our study sample was confined to women may
limit the scope of the present results. However, it is known that the
incidence of MUS is more common in women than in men (Smith,
Monson, & Ray, 1986; Stewart, 1990), making our findings rele-
vant for a majority of MUS patients. Nevertheless, other findings
(Van Diest et al., 2005) suggest important differences between
men and women in the symptom patterns of high symptom report-
ers. Investigating symptom perception of men in a similar para-
digm is therefore necessary. In addition, given our exclusion
criteria, it remains to be tested whether our findings generalize to
MUS patients with comorbid major psychiatric conditions.
By narrowing down the specific circumstances under which
MUS-related differences in symptom perception occur, the present
study contributes to the empirical underpinning of symptom per-
ception accounts of MUS in general. Moreover, our results are
particularly relevant for the respiratory domain. Dyspnea is the third
most frequently reported symptom in medicine while 14% of dyspnea
remains unexplained (Reid, Wessely, Crayford, & Hotopf, 2001).
Our findings may also have particular relevance for clinical prac-
tice. Physicians need to take into account that symptom reports
during low intensity physical sensations caused by physical exam-
inations or illnesses may trigger symptom schemata in MUS
patients that may bias and distort accurate reports of their physical
condition. The understanding that symptom perception is highly
variable within patients and dependent upon contextual influences
can also serve treatment purposes.
In sum, the present study corroborates in clinical MUS patients
our earlier observation in nonclinical groups: High MUS reporters
show lower correspondence between symptom ratings and their
physiological referents than do non-MUS control participants. In
addition, we observed that the MUS-related bias operates only at
times of weak, motivationally irrelevant somatic activity. During
intense physiological changes, however, no room is left for top-
down biases, and symptom reports are overall more physiology-
based, reflecting closely the bodily changes. Our findings further
suggest sensitization of subjective dyspnea feelings in MUS pa-
tients. Overall, the results argue for an important role for top-down
psychological processes in the symptom perception of patients
with MUS.
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